Nucleai Unveils Breakthrough AI Spatial Biomarker Advancements At AACR 2024

 


Nucleai, a spatial AI biomarker company, is set to present its cutting-edge developments in cancer research and diagnostics at the AACR Annual Meeting in San Diego from April 5-10, 2024. Their posters will unveil novel AI spatial biomarkers and advanced histopathology workflows, promising to revolutionize cancer treatment and diagnostics. In collaboration with Dr. Arutha Kulasinghe, Nucleai's first poster reveals a groundbreaking signature linked to immunotherapy outcomes in lung cancer. Leveraging their unique AI spatial biology solution, the research uncovers correlations between metabolic states and spatial distribution of cells, offering crucial insights into disease progression and treatment response. Their second poster introduces the H&E 2.0 algorithm, a significant leap in cancer pathology that automates tasks and improves accuracy, marking a stride toward more precise diagnosis and treatment. Driven by innovation, Nucleai integrates spatial biology with AI to extract actionable insights from pathology data, setting a new standard for precision medicine and enhancing patient care. Visit nucleai.ai/aacr2024 for more details on their AACR presence.

Read More - https://www.techdogs.com/tech-news/business-wire/nucleai-unveils-breakthrough-ai-spatial-biomarker-advancements-at-aacr-2024-with-the-potential-to-transform-cancer-diagnostics-and-treatments

Comments

Popular posts from this blog

Orlagh Neary, Former VP Of Quantum Ecosystem Engagement And GTM At Microsoft On Building Scalable And Safe AI And Quantum

Varun Srinivas Founder & CEO of Therix.ai and Co-Founder at Coditas on Building Real-World AI Solutions

MediaTek Vs. Snapdragon: Which Chipset Performs Better?